ArticleCell cycle (Georgetown, Tex.)2018

MiR-3606-3p inhibits systemic sclerosis through targeting TGF-β type II receptor.

Xiangguang Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.